BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China-Singapore Translational Medicine Center Advances CGT Industry Leadership

26th Jun 2023, the 13th Singapore Guangdong Collaboration Council was held in Singapore. During the event, leaders from both Governments wit...

July 12, 2023 | News

RGE Builds China's Largest Oleochemical Industry Integration Facility

The commissioning ceremony was attended by Belinda Tanoto, Managing Director of RGE China; Wang Minyan, Chairman of the China Cleaning Industry Associ...

July 12, 2023 | News

Doer Biologics Announces License Agreement with BioNTech

Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio's innovative discoveries to research, develop...

July 12, 2023 | News

Broncus Completes First Registered Clinical Trials of Targeted Lung Denervation System

The multi-center clinical randomized controlled trial on the ''treatment of Chronic Obstructive Pulmonary Disease (''COPD'') by targeted lung denervation a...

July 11, 2023 | News

HOYA Group PENTAX Medical Established Manufacturing, R & D and Service Center in China

The manufacturing site is going to produce PENTAX Medical endoscopic solutions for China. A state-of-the-art service center is to enhance customer ex...

July 11, 2023 | News

RemeGen and Innovent Collaborate on Clinical Trials for Advanced Solid Tumors

RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, announce...

July 10, 2023 | News

280 Bio receives IND approval from the FDA for YL-17231

80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...

July 10, 2023 | News

Transcenta Receives Approvals for Global Phase III Trial of Osemitamab (TST001)

To initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy for the first-line treatment ...

July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

July 10, 2023 | News

GeneQuantum Healthcare and Aimed Bio collaborate to develop 5 innovative ADC drugs

Since April of last year, GeneQuantum and Aimed Bio have been collaborating on the joint development of a FGFR3-targeting ADC named GQ1011/AMB302. The prog...

July 07, 2023 | News

GenScript Doubles cGMP sgRNA and Non-Viral DNA Payload Manufacturing Capacity

GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its cGMP manufacturing capacity...

July 07, 2023 | News

TiumBio and Hansoh Pharma Secure NMPA Approval for 'HS-10518/TU2670' Clinical Trial in China

TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis in Europe by the end of the year TiumBio C...

July 06, 2023 | News

China NMPA approves RareStone's pitolisant (Wakix) for the treatment of narcolepsy

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, announced that on June 30, the Chi...

July 05, 2023 | News

Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

The pivotal clinical trial approved in China will evaluate the efficacy and safety of Glecirasib as a single agent for the second line treatment ...

July 05, 2023 | News

Stay Connected